In short

Switching because your usual product is unavailable is common and clinically reasonable. What it is not is a straight swap. Different molecules mean.

By Alsen Walker · Updated September 22, 2026

Switching because your usual product is unavailable is common and clinically reasonable. What it is not is a straight swap. Different molecules mean re-titrating, a new prior authorization, and a starting dose your prescriber decides. Start the paperwork early, because that is usually slower than the clinical decision.

There is no reliable published dose equivalence between these molecules. Conversion tables circulate and they are not a substitute for a prescriber applying current prescribing information to your situation. Working out your own starting dose is how people end up taking considerably more than intended.

For how this fits into stopping and maintenance generally, see Stopping a GLP-1: What Happens and How to Plan It.

What a switch involves

Re-titration, usually. Starting lower than where you left off and working up, because tolerance to one molecule does not transfer cleanly to another.

A new authorization under different criteria. Approval for one product says nothing about another, and this is where switches stall.

A different device, with different instructions for use. Read them rather than assuming your technique transfers.

A period of adjustment as side effects flare and settle again, in the same pattern as any dose change.

Sequence it properly

Confirm the alternative is actually available before starting anything. Switching to a second product that is also short achieves nothing.

Check your formulary for the alternative, and note whether prior authorization or step therapy applies.

Have the authorization filed before your current supply runs out. A gap between products is the avoidable failure here.

Ask your prescriber what starting dose they intend and why, so you know what to expect.

Do not overlap

Never take both products in the same period, and this matters especially where they share an active ingredient under different brand names.

If a switch leaves you with supply of both, ask your pharmacist what to do with the surplus rather than using it up.

Same molecule, different brand

Worth distinguishing. Moving between two brands of the same active ingredient is a different situation from moving between molecules, though it still requires a prescriber decision on dose and still needs its own authorization.

Neither is something to arrange by working from an online chart.

Switching back later

Common once supply returns, and it means the same process again: re-titration and another authorization.

Given that, it is worth asking whether staying on the new product is reasonable rather than switching twice. Two adjustment periods have a cost.

Tell your prescriber it was supply

Interruptions caused by shortage are relevant information for authorizations and sometimes for continuation criteria, where a gap might otherwise look like non-adherence.

Frequently asked questions

Can I switch at an equivalent dose?
There is no reliable published equivalence. Your prescriber decides.

Will side effects return?
Usually during re-titration, settling as before.

Do I need a new prior authorization?
Yes, under the new product’s criteria. Start it early.

Will I lose progress?
A short gap or a lower starting dose is unlikely to undo much. Tell your prescriber if it is prolonged.

Should I switch back when supply returns?
Worth weighing against another adjustment period. Ask whether staying put is reasonable.

What if the alternative does not suit me?
Tell your prescriber. Holding a dose or stepping down are options before abandoning it.

Alsen Walker is a health writer and researcher at GLP1Hub with five years of experience researching and writing health and medical content. He works in a medical-field role alongside his undergraduate studies. At GLP1Hub he researches GLP-1 weight loss programs, pricing and insurance rules, and checks claims against FDA prescribing information, published clinical trials and official government sources. Alsen is not a physician, and his articles are general information, not medical advice.